Fluticasone Propionate
Brand Names: Childrens Flonase Allergy Relief, Allergy Relief, Childrens Allergy Relief, Flovent Hfa, 24 Hour Allergy Nasal, Flovent Diskus
Methodology & AI Transparency ⓘ
Fluticasone Propionate Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Fluticasone Propionate HFA is indicated for the maintenance treatment of asthma as prophylactic therapy in adult and pediatric patients aged 4 years and older.
- 2 Real-world patient consensus: 80% patient "Worth It" rating across 6 anonymous logs for Fluticasone Propionate (RxNorm 895999).
- 3 Typical cash cost range: Dispensing cost comparison spans $7.82 mail/discount cash up to $34.50 uninsured retail (federal NADAC $13.5803).
- 4 Top reported side effects / signs: Primary clinical safety signals tracked in FAERS for Fluticasone Propionate include headache (8.8%), cough (5.8%), nasopharyngitis (6.9%).
Ask our AI Specialists anything about Fluticasone Propionate
Fluticasone Propionate Mechanism, CYP450 Pathways & DailyMed Monograph
Fluticasone Propionate HFA is indicated for the maintenance treatment of asthma as prophylactic therapy in adult and pediatric patients aged 4 years and older. Limitations of Use Fluticasone Propionate HFA is not indicated for the relief of acute bronchospasm. Fluticasone Propionate HFA is an inhaled corticosteroid indicated for: ; Maintenance treatment of asthma as prophylactic therapy in adult and pediatric patients aged 4 years and older. ( 1 ) Limitations of use: Not indicated for relief of acute bronchospasm. ( 1 )
12.1 Mechanism of Action Fluticasone propionate is a synthetic trifluorinated corticosteroid with anti-inflammatory activity. Fluticasone propionate has been shown in vitro to exhibit a binding affinity for the human glucocorticoid receptor that is 18 times that of dexamethasone, almost twice that of beclomethasone‑17‑monopropionate (BMP), the active metabolite of beclomethasone dipropionate, and over 3 times that of budesonide. Data from the McKenzie vasoconstrictor assay in man are consistent with these results. The clinical significance of these findings is unknown.
With Approximately 6–13 hours terminal plasma half-life for Fluticasone Propionate residence kinetics and ~1% systemic bioavailability (Fluticasone Propionate) bioavailability, Fluticasone Propionate undergoes hepatic oxidation via cyp3a4 followed by renal and biliary excretion of fluticasone propionate metabolites and establishes therapeutic activity over peak plasma concentration (tmax) reached 1–3 hours post-dose for fluticasone propionate.
Standard adult regimens span 50 ug/1 Spray, Metered, .5 mg/g Cream, 44 ug/1 Aerosol, Metered, 250 ug/1 Powder, Metered, .05 mg/g Ointment. Prescribers screen specifically against fluticasone propionate hfa is contraindicated in the following conditions:; primary treatment of status asthmaticus or other acute episodes of asthma where intensive measures are required .; hypersensitivity to any of the ingredients ., while community micro-logs most frequently note nausea (8.9% of reports), headache (8.8% of reports), nasopharyngitis (6.9% of reports).
Strong CYP3A4 blockade slows first-pass metabolism of Fluticasone Propionate, elevating systemic AUC exposure.
Potent CYP3A4 modulators alter hepatic clearance of Fluticasone Propionate, shifting steady-state plasma concentrations.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Fluticasone Propionate HFA is contraindicated in the following conditions:
- Primary treatment of status asthmaticus or other acute episodes of asthma where intensive measures are required .
- Hypersensitivity to any of the ingredients .
Logged Side-Effect Incidence (6 Reports)
Fluticasone Propionate Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Fluticasone Propionate)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Benefits and safety of Once-Daily Vilanterol/Fluticasone furoate MDI in: What a 330-Participant Study Found Once daily VI/FF pMDI was non-inferior to twice daily FOR/FP pMDI in patients with persistent asthma. The Journal of asthma : official journal of the Association for the Care of Asthma • 2024-10-15 • Phase III Randomized Trial | N = 330 | 93/100 | PMID 38488853 ↗ |
| Can This Approach Help? Inside the Latest Research on Dupilumab is efficacious for eosinophilic esophagitis irrespective of prior Dupilumab was efficacious in patients with EoE irrespective of prior treatments/interventions. Expert review of gastroenterology & hepatology • 2025-01-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 39909733 ↗ |
| Can This Approach Help? Inside the Latest Research on Once-daily fluticasone furoate/vilanterol vs once-daily fluticasone furoate in FF/VI significantly improved weighted mean FEV 1 (0-4 hours; participants aged 5-17 years), but not ΔAM PEF (participants aged 5-11 years) vs FF. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology • 2024-11-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 38936466 ↗ |
| Clinic vs. Home Spirometry: Which Works Better for Monitoring Lung Function in Patients With Asthma? This post hoc comparison of home and clinic spirometry is the largest conducted in asthma. Chest • 2023-11-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 37385337 ↗ |
| Can This Approach Help? Inside the Latest Research on Once-daily, single-inhaler indacaterol/mometasone versus twice-daily Once-daily, single-inhaler IND/MF high-dose improved lung function with better asthma control, reduced asthma exacerbations with comparable safety versus twice-daily SAL/FLU high-dose. The Journal of asthma : official journal of the Association for the Care of Asthma • 2022-08-15 • Phase III Randomized Trial | N = 107 | 88/100 | PMID 34346266 ↗ |
Fluticasone Propionate Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $13.5803/unit (~$407.41/30u) | Wholesale baseline |
| Mark Cuban Cost Plus Drugs (Mail-Order Generic) | Public Wholesale Price List (NADAC + 15% + pharmacy fee) | $7.82 / mo | Formulary listing ↗ |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $34.50 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 6 Anonymous DotMD Community Micro-Logs | $8.99 / mo | View logs ↓ |
| Sesame Direct Cash-Pay Prescriber Network (Licensed Telehealth Cash Program) | State-licensed clinician review • ~1d mail fulfillment | $29.00 consult | Program details |
| Virtual Psychiatric Medication Management (Licensed Telehealth Cash Program) | State-licensed clinician review • ~1d mail fulfillment | $39.00 consult | Program details |
Fluticasone Propionate Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Fluticasone Propionate RxNorm Concept ID | 895999 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $13.5803 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $34.50 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $7.82 / mo (Cost Plus Drugs) | Mark Cuban Cost Plus Public API |
| Real-World Patient Consensus | 80.00% Worth It (6 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Fluticasone Propionate Patient Community, Cohort Filters & Dosage Logs
Deterministic Fluticasone Propionate reference combining NIH RxNorm (895999), Medicaid NADAC ($13.5803/unit), and anonymous cohort outcomes (80% Worth It).
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Fluticasone Propionate community threads and patient logs by age, biological sex, dosage, and treatment duration.